Hum. Reprod. Advance Access originally published online on March 31, 2005
Human Reproduction 2005 20(7):1814-1819; doi:10.1093/humrep/deh873
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism
1 IVF Unit, Department of Obstetrics and Gynecology, and 2 Institute of Hormone Research, Shaare-Zedek Medical Center, Ben Gurion University of the Negev, Jerusalem, Israel
3 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Jerusalem 91031, Israel. Email: gevat{at}szmc.org.il
BACKGROUND: Anti-Mullerian hormone (AMH) is expressed in pre- and small-antral follicles. High serum levels are found in women with polycystic ovaries (PCO), accordant with their increased content of small follicles. To evaluate the relationship between AMH, folliculogenesis and hyperandrogenism, we compared serum AMH levels between women with PCO with and without hyperandrogenism and normal controls during controlled ovarian hyperstimulation (COH). METHODS: Nineteen women with PCO and hyperandrogenism (group A), 10 women with PCO but no hyperandrogenism (group B) and 23 ovulatory women with normal ovarian morphology (group C, controls) underwent COH with the long protocol. Serum levels of AMH, estradiol, androstenedione and follicular tracking were determined before gonadotropins treatment (day 0) and every 2–4 days up to the day of HCG administration. RESULTS: AMH levels declined gradually throughout COH in the three groups, but remained higher in groups A and B compared with the controls. Significantly higher levels were found in group A compared with group B, despite comparable numbers of small follicles. Multiple regression analysis revealed that both the number of small follicles and serum androgens were correlated to AMH. CONCLUSIONS: Women with PCO have higher serum AMH levels during COH than controls. Hyperandrogenism is associated with an additional increase in AMH. It is conceivable that hyperandrogenism may reflect more severe disruption of folliculogenesis in women with PCO or may affect AMH secretion.
Key words: anti-Mullerian hormone/controlled ovarian hyperstimulation/hyperandrogenism/polycystic ovaries
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Das, D.J. Gillott, E. Saridogan, and O. Djahanbakhch Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome Hum. Reprod., September 1, 2008; 23(9): 2122 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Catteau-Jonard, P. Pigny, A.-C. Reyss, C. Decanter, E. Poncelet, and D. Dewailly Changes in Serum Anti-Mullerian Hormone Level during Low-Dose Recombinant Follicular-Stimulating Hormone Therapy for Anovulation in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4138 - 4143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Moran, M. Noakes, P. M. Clifton, and R. J. Norman The Use of Anti-Mullerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3796 - 3802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Wachs, M. S. Coffler, P. J. Malcom, and R. J. Chang Serum Anti-Mullerian Hormone Concentrations Are Not Altered by Acute Administration of Follicle Stimulating Hormone in Polycystic Ovary Syndrome and Normal Women J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1871 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pellatt, L. Hanna, M. Brincat, R. Galea, H. Brain, S. Whitehead, and H. Mason Granulosa Cell Production of Anti-Mullerian Hormone Is Increased in Polycystic Ovaries J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 240 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pigny, S. Jonard, Y. Robert, and D. Dewailly Serum Anti-Mullerian Hormone as a Surrogate for Antral Follicle Count for Definition of the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 941 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Visser, F. H de Jong, J. S E Laven, and A. P N Themmen Anti-Mullerian hormone: a new marker for ovarian function Reproduction, January 1, 2006; 131(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|